Estrone

Estrone (E1) is a naturally occurring estrogen primarily produced in the ovaries, adipose tissue, and adrenal glands, and serves as a key precursor to estradiol. Researchers primarily study estrone for its role in postmenopausal health and cardiovascular function. Studies suggest that E1 induces endothelium-dependent vasodilation and activates signaling pathways that mitigate oxidative stress and improve vascular function, particularly in postmenopausal models. Additionally, clinical evidence indicates that estrone metabolism is intricately linked to breast cancer development, with enzymes like 17beta-hydroxysteroid dehydrogenase playing crucial roles in modulating estrogen levels within tumors. Current research continues to explore estrone's physiological effects and its implications for hormone-related conditions, highlighting its significance in both basic and clinical endocrinology.

Estrone (E1), also known as oestrone, is an endogenous estrogen and a member of the steroid hormone class. It is primarily produced in the ovaries, adipose tissue, and adrenal glands. Estrone is one of the three major estrogens in humans, alongside estradiol and estriol, and is particularly significant in postmenopausal women where it serves as the predominant circulating estrogen. Researchers have found that estrone serves as both a precursor and a metabolite of estradiol, contributing to the dynamic balance of estrogenic activity in the body. Estrone's primary physiological roles include its involvement in the regulation of the menstrual cycle and reproductive system, as well as its influence on secondary sexual characteristics. Research has also focused on its role in cardiovascular health, particularly in postmenopausal women, where it has been observed to improve endothelial function and reduce oxidative stress. Estrone acts through estrogen receptors, primarily the classic estrogen receptors (ERα and ERβ), and has been shown to activate the PI3K/Akt pathway, leading to the modulation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling. This cascade is crucial for its vasodilatory effects and potential cardiovascular benefits. Pharmacokinetically, estrone exhibits significant inter- and intra-individual variability. It is interconvertible with estradiol, and its metabolism is influenced by liver enzymes such as cytochrome P450. Oral administration leads to substantial first-pass metabolism, affecting its bioavailability. Clinically, estrone is used in hormone replacement therapy, particularly in postmenopausal women, although its use is less common than other estrogens like estradiol. Regulatory standing varies by region, with prescription requirements in place in many countries.

Estrone acts primarily through estrogen receptors ERα and ERβ, leading to the activation of the PI3K/Akt pathway. This activation results in the modulation of nitric oxide (NO) and cGMP signaling, which contributes to its vasodilatory effects and potential cardiovascular benefits.

Estrone (E1) primarily acts through classic estrogen receptors (ERα and ERβ) to induce endothelium-dependent vasodilation by activating the PI3K/Akt pathway and enhancing nitric oxide (NO) signaling, leading to increased cGMP levels. It also modulates oxidative stress by upregulating antioxidant enzymes like superoxide dismutase (SOD) and catalase (CAT), while decreasing the expression of NADPH oxidase 4 (NOX4). Additionally, E1 serves as a precursor to estradiol (E2) via the action of 17β-hydroxysteroid dehydrogenase (17β-HSD), facilitating its conversion in tissues, particularly in hormone-dependent breast carcinoma.

Current evidence is limited regarding the long-term effects of estrone on cardiovascular health, particularly in diverse populations beyond ovariectomized animal models. Further research is needed to clarify the role of estrone in the development of hormone-dependent breast cancers, specifically the interplay between estrone and intratumoral enzymes like 17beta-HSD and their impact on estrogen receptor status. Additionally, larger randomized controlled trials are necessary to investigate the therapeutic potential of estrone in managing postmenopausal symptoms and its safety profile in various demographic groups.